Yemaachi Biotech Analysis
What is Yemaachi Biotech?
Yemaachi Biotech develops next-generation cancer drugs through clinical genomic research in Africa, focusing on precision oncology for diverse populations.
Employees
16
Founded
2020
Revenue
$2.8-6.2M
Company Stage
Seed
YC Batch
S21
Product Features & Capabilities
- GeneStrat™ EGFR ctDNA, non-invasive blood-based test for NSCLC, fast and accurate results, supports treatment decisions
- Sheba HPV Test, self-sampling and molecular diagnostics for HPV screening, detects 15 cancer-causing strains
- SMA Genetic Testing Program, free blood test for Spinal Muscular Atro
Who are the founders of Yemaachi Biotech
Investors
- Yemaachi Biotech has attracted over $4 million in investment.
- The funding primarily comes from African investors and the Bill and Melinda Gates Foundation.
